Veeva Summit Keynote: Veeva Development Cloud Vision

This video keynote from Veeva Summit outlines Veeva's strategic vision for building an integrated "industry cloud" for life sciences, the Veeva Development Cloud, which spans the full product lifecycle from clinical to regulatory, quality, and safety on the Vault platform. The speaker details significant platform enhancements, updates across their application suites, and introduces the ambitious Digital Trials Platform. The discussion also touches on Veeva's recent conversion to a Public Benefit Corporation, emphasizing a long-term commitment to balancing stakeholder interests. A key segment features an interview with Jörg Möller of LEO Pharma, highlighting their partnership with Veeva on digital trials and the anticipated benefits of shortening development timelines and reducing costs.

Key Takeaways:

• Veeva's overarching strategy is to create a unified industry cloud for life sciences, integrating clinical, regulatory, quality, and safety operations on the Vault platform to enhance efficiency and effectiveness across the product lifecycle.
• Recent Vault platform enhancements include Microsoft Office integration with collaborative authoring and Excel report templates, the upcoming Vault Mobile app for secure document access, and the new Action UI for a more productive and modern user experience.
• The Vault Quality suite is expanding with new offerings like Vault Validation Management for digital validation processes, Vault LIMS for optimizing quality control, and Veeva Learn GxP, a content library of accredited e-learning courses for GxP training.
• Veeva's Clinical (CTMS, EDC, CDB) and Safety solutions are maturing rapidly, demonstrating strong adoption and enterprise-wide implementation by major pharmaceutical companies, reflecting the industry's need for integrated solutions in these complex areas.
• A major multi-year initiative is the Veeva Digital Trials Platform, designed to fundamentally improve clinical trial information flow by connecting sponsors, patients, and research sites through applications like Site Connect, e-Consent, e-PRO, virtual visits, e-Source, and sensor data, aiming to enhance patient experience and streamline operations.
• Partnerships with early adopter customers, such as LEO Pharma's collaboration on the digital trials platform, are crucial for product development and validation, with LEO Pharma targeting a 25% reduction in clinical development timelines and costs.
• Veeva's conversion to a Public Benefit Corporation reinforces its commitment to a balanced, long-term approach that prioritizes customer and employee success alongside shareholder value, particularly as technology becomes increasingly vital to life sciences.